Trials / Conditions / Astrocytoma, IDH-Mutant, Grade 2
Astrocytoma, IDH-Mutant, Grade 2
3 registered clinical trials studyying Astrocytoma, IDH-Mutant, Grade 2 — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Suspended | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblasto NCT06860594 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519 | Nuvation Bio Inc. | Phase 3 |
| Active Not Recruiting | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytom NCT03528642 | National Cancer Institute (NCI) | Phase 1 |